Monoclonal antibody-targeted polymeric nanoparticles for cancer therapy - future prospects

Journal of Chemical Technology and Biotechnology

Volumn 90, Issue 7, 2015, Pages 1169-1176

  Goodall, Stephen ^a   Jones, Martina L ^a   Mahler, Stephen ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibody; Drug delivery; Fragment; Immunomicelle; Immunoparticle; Nanoparticles; scFv

Indexed keywords

DISEASES; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; MONOCLONAL ANTIBODIES; NANOPARTICLES; POLYMERS; SURFACE PLASMON RESONANCE; TUMORS;

FRAGMENT; IMMUNOMICELLE; IMMUNOPARTICLE; LIPOSOMAL NANOPARTICLES; LIVING RADICAL POLYMERISATION; NANOPARTICLE STRUCTURES; POLYMERIC NANOPARTICLES; SCFV;

ANTIBODIES;

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSFERRIN RECEPTOR;

CANCER CELL; CANCER THERAPY; CELL SURVIVAL; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; ENDOCYTOSIS; NANOMEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; TUMOR CELL;

EID: 84930368693     PISSN: 02682575     EISSN: 10974660     Source Type: Journal    
DOI: 10.1002/jctb.4555     Document Type: Review

References (82)

1. Shuptrine CW, Surana R and Weiner LM, Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 22:3-13 (2012).
2. Scott AM, Wolchok JD and Old LJ, Antibody therapy of cancer. Nat Rev Cancer 12:278-287 (2012).
3. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, De Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL and Chen R, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clinic Oncol 30:2183-2189 (2012).
4. Mullard A, 2013 FDA drug approvals. Nat Rev Drug Discov 13:85-89 (2014).
5. Sievers EL and Senter PD, Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15-29 (2013).
6. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF and Farokhzad OC, Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971-3010 (2012).
7. Sanna V, Pala N and Sechi M, Targeted therapy using nanotechnology: focus on cancer. Int J Nanomed 9:467-483 (2014).
8. Duncan R, Polymer therapeutics as nanomedicines: new perspectives. Current Opin Biotechnol 22:492-501 (2011).
9. Awwad M, Strome PG, Gilman SC and Axelrod HR, Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions. Cancer Immunol Immunother 38:23-30 (1994).
10. Kamphuis MMJ, Johnston APR, Such GK, Dam HH, Evans RA, Scott AM, Nice EC, Heath JK and Caruso F, Targeting of cancer cells using click-functionalized polymer capsules. J Am Chem Soc 132:15881-15883 (2010).
11. Jewett JC and Bertozzi CR, Cu-free click cycloaddition reactions in chemical biology. Chem Soc Rev 39:1272-1279 (2010).
12. Leung MKM, Hagemeyer CE, Johnston APR, Gonzales C, Kamphuis MMJ, Ardipradja K, Such GK, Peter K and Caruso F, Bio-click chemistry: enzymatic functionalization of PEGylated capsules for targeting applications. Angewandte Chemie - Int Ed 51:7132-7136 (2012).
13. van der Meel R, Vehmeijer LJC, Kok RJ, Storm G and van Gaal EVB, Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 65:1284-1298 (2013).
14. Bazak R, Houri M, El Achy S, Kamel S and Refaat T, Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol doi: 10.1007/300432-014-1767-3 (2014).
15. MacDiarmid JA and Brahmbhatt H, Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Current Opin Biotechnol 22:909-916 (2011).
16. Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ and Bohlen P, Monoclonal antibody therapeutics and apoptosis. Oncogene 22:9097-9106 (2003).
17. Master AM and Sen Gupta A, EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine 7:1895-1906 (2012).
18. Xu S, Olenyuk BZ, Okamoto CT and Hamm-Alvarez SF, Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev 65:121-138 (2013).
19. Sapra P and Allenz TM, Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62:7190-7194 (2002).
20. Suen WLL and Chau Y, Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells. J Pharm Pharmacol 66:564-573 (2014).
21. Akinc A and Battaglia G, Exploiting endocytosis for nanomedicines. Cold Spring Harbor Perspect Biol 5(11):a016980 (2013).
22. Myers DE, Yiv S, Qazi S, Ma H, Cely I, Shahidzadeh A, Arellano M, Finestone E, Gaynon PS, Termuhlen A, Cheng J and Uckun FM, CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. Integrative Biol 6:766-780 (2014).
23. Patel AR, Chougule M and Singh M, EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer. Pharm Res 31(10):2796-809 (2014).
24. Song S, Qi H, Xu J, Guo P, Chen F, Li F, Yang X, Sheng N, Wu Y and Pan W, Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting. Pharm Res doi: 10.1007/s11095-014-1393-4 (2014).
25. Sorkin A and Goh LK, Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315:683-696 (2009).
26. Grandal MV and Madshus IH, Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med 12:1527-1534 (2008).
27. Sunada H, Magun BE, Mendelsohn J and MacLeod CL, Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Nat Acad Sci USA 83:3825-3829 (1986).
28. Vega J, Ke S, Fan Z, Wallace S, Charsangavej C and Li C, Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Pharmaceut Res 20:826-832 (2003).
29. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R and Rochlitz C, Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 13:1234-1241 (2012).
30. Mitri Z, Constantine T and O'Regan R, The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Practice 2012:743193 (2012).
31. Gutierrez C and Schiff R, HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55-62 (2011).
32. Minami T, Kijima T, Kohmo S, Arase H, Otani Y, Nagatomo I, Takahashi R, Miyake K, Higashiguchi M, Morimura O, Ihara S, Tsujino K, Hirata H, Inoue K, Takeda Y, Kida H, Tachibana I and Kumanogoh A, Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis. Sci Rep 3:2669 (2013).
33. Burris Iii HA, Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 11:807-819 (2011).
34. Hoang B, Ekdawi SN, Reilly RM and Allen C, Active targeting of block copolymer micelles with trastuzumab fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts. Mol Pharmaceut 10:4229-4241 (2013).
35. Chiang CS, Hu SH, Liao BJ, Chang YC and Chen SY, Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds. Nanomed:Nanotechnol Biol Med 10:99-107 (2014).
36. Ulbrich K, Hekmatara T, Herbert E and Kreuter J, Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71:251-256 (2009).
37. Bostwick DG, Pacelli A, Blute M, Roche P and Murphy GP, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256-2261 (1998).
38. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R and Bander NH, Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055-4060 (1998).
39. Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Hoven TVG, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R and Zale S, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Translational Med 4(128):128ra39 (2012).
40. Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A and Sofou S, Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer. J Nucl Med 55:107-114 (2014).
41. Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG and Frangioni JV, Renal clearance of quantum dots. Nature Biotechnol 25:1165-1170 (2007).
42. Yamashita F and Hashida M, Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev 65:139-147 (2013).
43. Hillaireau H and Couvreur P, Nanocarriers' entry into the cell: relevance to drug delivery. Cellular Mol Life Sci 66:2873-2896 (2009).
44. Maeda H, Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate Chem 21:797-802 (2010).
45. Lammers T, Kiessling F, Hennink WE and Storm G, Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Controlled Release 161:175-187 (2012).
46. Zhou Y and Kopeček J, Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Targeting 21:1-26 (2013).
47. Netti PA, Baxter LT, Boucher Y, Skalak R and Jain RK, Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 55:5451-5458 (1995).
48. Pirollo KF and Chang EH, Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol 26:552-558 (2008).
49. Wang J, Byrne JD, Napier ME and Desimone JM, More effective nanomedicines through particle design. Small 7:1919-1931 (2011).
50. Mahon E, Salvati A, Baldelli Bombelli F, Lynch I and Dawson KA, Designing the nanoparticle-biomolecule interface for 'targeting and therapeutic delivery'. J Controlled Release 161:164-174 (2012).
51. Ai J, Biazar E, Jafarpour M, Montazeri M, Majdi A, Aminifard S, Zafari M, Akbari HR and Rad HG, Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomed 6:1117-1127 (2011).
52. Kim JK, Kim HJ, Chung JY, Lee JH, Young SB and Kim YH, Natural and synthetic biomaterials for controlled drug delivery. Arch Pharmacol Res 37:60-68 (2014).
53. DOXIL approved by FDA. AIDS Patient Care 9:306 (1995).
54. Galvin P, Thompson D, Ryan KB, McCarthy A, Moore AC, Burke CS, Dyson M, MacCraith BD, Gun'Ko YK, Byrne MT, Volkov Y, Keely C, Keehan E, Howe M, Duffy C and MacLoughlin R, Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cellular Mol Life Sci 69:389-404 (2012).
55. Chiefari J, Chong YK, Ercole F, Krstina J, Jeffery J, Le TPT, Mayadunne RTA, Meijs GF, Moad CL, Moad G, Rizzardo E and Thang SH, Living free-radical polymerization by reversible addition - fragmentation chain transfer: the RAFT process. Macromolecules 31:5559-5562 (1998).
56. Wang JS and Matyjaszewski K, Controlled/'living' radical polymerization. Halogen atom transfer radical polymerization promoted by a Cu(I)/Cu(II) redox process. Macromolecules 28:7901-7910 (1995).
57. Hawker CJ, Bosman AW and Harth E, New polymer synthesis by nitroxide mediated living radical polymerizations. Chem Rev 101:3661-3688 (2001).
58. Matyjaszewski K, Atom transfer radical polymerization (ATRP): current status and future perspectives. Macromolecules 45:4015-4039 (2012).
59. Zhu J and Shi X, Dendrimer-based nanodevices for targeted drug delivery applications. J Mater Chem B 1:4199-4211 (2013).
60. Zhou Y, Huang W, Liu J, Zhu X and Yan D, Self-assembly of hyperbranched polymers and its biomedical applications. Adv Mater 22:4567-4590 (2010).
61. Duncan R and Vicent MJ, Polymer therapeutics - prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 65:60-70 (2013).
62. Boyer C, Huang X, Whittaker MR, Bulmus V and Davis TP, An overview of protein-polymer particles. Soft Matter 7:1599-1614 (2011).
63. Velonia K, Protein-polymer amphiphilic chimeras: recent advances and future challenges. Polym Chem 1:944-952 (2010).
64. Sumerlin BS, Proteins as initiators of controlled radical polymerization: grafting from via ATRP and RAFT. ACS Macro Lett 1:141-145 (2012).
65. Sawant RR, Jhaveri AM and Torchilin VP, Immunomicelles for advancing personalized therapy. Adv Drug Deliv Rev 64:1436-1446 (2012).
66. Nyström AM and Wooley KL, Thiol-functionalized shell crosslinked knedel-like (SCK) nanoparticles: a versatile entry for their conjugation with biomacromolecules. Tetrahedron 64:8543-8552 (2008).
67. Torchilin VP, Lukyanov AN, Gao Z and Papahadjopoulos-Sternberg B, Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Nat Acad Sci USA 100:6039-6044 (2003).
68. Jin C, Qian N, Zhao W, Yang W, Bai L, Wu H, Wang M, Song W and Dou K, Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab′)2 for hepatocellular carcinoma. Biomacromolecules 11:2422-2431 (2010).
69. Chen JP, Yang HJ and Hoffman AS, Polymer-protein conjugates. I. Effect of protein conjugation on the cloud point of poly(N-isopropylacrylamide). Biomaterials 11:625-630 (1990).
70. Hong CY, You YEZI and Pan CY, Synthesis and characterization of well-defined diblock and triblock copolymers of poly(N-isopropylacrylamide) and poly(ethylene oxide). J Polym Sci Part A: Polym Chem 42:4873-4881 (2004).
71. Li G, Song S, Guo L and Ma S, Self-assembly of thermo- and pH-responsive poly(acrylic acid)-b-poly(N-isopropylacrylamide) micelles for drug delivery. J Polym Sci Part A: Polym Chem 46:5028-5035 (2008).
72. Huang CJ and Chang FC, Polypeptide diblock copolymers: syntheses and properties of poly(N-isopropylacrylamide)-b-polylysine. Macromolecules 41:7041-7052 (2008).
73. Zhao Y, Shi X, Gao H, Zhang L, Zhu F and Wu Q, Thermo- and pH-sensitive polyethylene-based diblock and triblock copolymers: Synthesis and self-assembly in aqueous solution. J Mater Chem 22:5737-5745 (2012).
74. Cheng R, Meng F, Ma S, Xu H, Liu H, Jing X and Zhong Z, Reduction and temperature dual-responsive crosslinked polymersomes for targeted intracellular protein delivery. J Mater Chem 21:19013-19020 (2011).
75. Tao CT and Young TH, Thermosensitive nanoparticles conjugating with CD34 antibody and its solution peroperties. Biomed Eng - Applic Basis Commun 18:222-228 (2006).
76. Qian C, Wang Y, Chen Y, Zeng L, Zhang Q, Shuai X and Huang K, Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials 34:6175-6184 (2013).
77. Tao L, Kaddis CS, Ogorzalek Loo RR, Grover GN, Loo JA and Maynard HD, Synthetic approach to homodimeric protein-polymer conjugates. Chem Commun 2148-2150 doi: 10.1039/b822799c (2009).
78. Tao L, Xu J, Gell D and Davis TP, Synthesis, characterization, and bioactivity of mid-functional polyHPMA-lysozyme bioconjugates. Macromolecules 43:3721-3727 (2010).
79. Li M, De P, Gondi SR and Sumerlin BS, Responsive polymer-protein bioconjugates prepared by RAFT polymerization and copper-catalyzed azide-alkyne click chemistry. Macromol Rapid Commun 29:1172-1176 (2008).
80. Goodall S, Howard CB, Jones ML, Munro T, Jia Z, Monteiro MJ and Mahler S, An EGFR targeting nanoparticle self assembled from a thermoresponsive polymer. J Chem Technol Biotechnol doi: 10.1002/jctb.4509 (2014).
81. Heredia KL, Bontempo D, Ly T, Byers JT, Halstenberg S and Maynard HD, In situ preparation of protein - 'Smart' polymer conjugates with retention of bioactivity. J Am Chem Soc 127:16955-16960 (2005).
82. Gao W, Liu W, Mackay JA, Zalutsky MR, Toone EJ and Chilkoti A, In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics. Proc Nat Acad Sci USA 106:15231-15236 (2009).